Nepicastat

Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 9, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, OPEX, ACOR, SG, Therapy, GAAP, Esteve, EBITDA, Government, Alkermes, Biotie Therapies, R, Acorda Therapeutics, Catalent, Cryptocurrency, Pharmaceutical industry, Video game, Reinsurance, Clothing, Music, Bookkeeping, Biogen, Açorda, 4-Aminopyridine, Nepicastat

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.
  • “Acorda’s operating and financial performance improved throughout the year, meeting our financial guidance for 2022 AMPYRA net revenue, INBRIJA U.S. net revenue, cash, and adjusted OPEX.
  • For the quarter ended December 31, 2022, the Company reported AMPYRA net revenue of $18.8 million, a 16.6% decrease compared to the same quarter in 2021.
  • Additionally, for the quarter ended December 31, 2022, the Company reported FAMPYRA royalty revenues of $2.7 million, a 25.1% decrease compared to the same quarter in 2021.

Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals

Retrieved on: 
Monday, August 29, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, Phenelzine, COVID-19, Security (finance), Workforce, Technology, ACOR, Research, Therapy, 4-Aminopyridine, Achievement, Tranylcypromine, Lists of diseases, Judgement, Consultant, Acorda Therapeutics, Inhalation, U.S. Securities and Exchange Commission, Goal, Patent, Tablet, OFF, Nasdaq, Failure, Risk, Açorda, Intellectual property, Health, Forward-looking statement, Patient, Travel, Pharmaceutical industry, Nepicastat

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a license agreement relating to its preclinical asset, Nepicastat, with Asieris Pharmaceuticals, a biotechnology company headquartered in China.
  • Under the terms of the agreement, Acorda will receive an upfront payment of $500,000, and up to an additional $7 million based on the achievement of regulatory milestones.
  • Acorda will also receive a royalty on future net sales.
  • Nepicastat is a small molecule drug and the license agreement provides for its development for all non-psychiatric indications and therapeutic uses.